LifeSpan BioSciences to release 20,000 immunohistochemistry-validated reagent antibodies Leader in antibody evaluation and validation expands focus to include development and sales of antibodies validated for use in immunohistochemistry
13 Jun 2008 -
LifeSpan BioSciences, Inc., announced an initiative to release 20,000 immunohistochemistry-validated reagent antibodies over the next four years. The leader in immunohistochemistry (IHC) antibody validation research since 1995, LifeSpan expanded its product focus to include the development and sale of IHC-validated antibodies in Q4 2006. To date, LifeSpan has built a catalog of more than 37,000 reagent antibodies, including more than 2,000 antibodies validated for use in immunohistochemistry. The company intends to expand its IHC-validated reagent antibody catalog at the rate of 5,000 per year.
"We have a tremendous opportunity to leverage our leadership position in antibody validation to become the dominant provider of high-quality antibodies to the research and pharmaceutical communities," said Glenna Burmer, M.D., Ph.D., chief scientific officer and executive vice president of LifeSpan. "This is a very exciting time for LifeSpan. Our experience providing IHC services to over 300 pharmaceutical and biotech companies for the past 12 years positions us as uniquely capable of identifying the best antibodies for future diagnostic and therapeutic applications."
Additional information
LifeSpan BioSciences, Inc. Seattle, WA , United States of America